Eleven Biotherapeutics Inc. (EBIO)

3.29 +0.64 (+24.151%)

IEX Real-Time Price

May 16, 2018 EST.

NASDAQ Global Market : Healthcare

Prev Close 2.65

Price Open 2.74

Volume: 15.59M

Avg Volume: 6.27M

Market Cap: 157.23M

P/E Ratio -3.29

52 Wk Range 0.6201-3.5



EBIO Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-04-30
46.75M
4.54M
0.78
9.71%

2018-04-13
42.06M
1.25M
0.46
2.96%

2018-03-29
42.06M
1.34M
1.20
3.19%

2018-03-15
42.06M
2.45M
2.90
5.82%




EBIO Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-05-15
Q1 2018
N/A
-0.13 (1)
-0.11
0.02

2018-05-03
Q1 2018
N/A
-0.18 (1)
0.00
0.00

2018-04-04
Q4 2017
N/A
0.00 (0)
-0.22
0.00

2018-03-30
Q4 2017
N/A
-0.17 (1)
0.00
0.00

News

Midday Gainers / Losers (05/16/2018) (2018-05-16 13:00 SeekingAlpha)

Gainers: IHT +50% . BLNK +36% . EBIO +21% . GEMP +18% . VNET +18% . FSI +16% . ABAX +16% . BBOX +13% . ASNA +14% . NSPR +14% . More news on: Innsuites Hospitality Trust, Blink Charging Co., Eleven Biotherapeutics, Inc., Stocks on the move, , Read more ….

 

Eleven Biotherapeutics changes its name to Sesen Bio (2018-05-16 07:59 SeekingAlpha)

Eleven Biotherapeutics (NASDAQ: EBIO ) announces its name change to Sesen Bio, Inc. Sesen Bio will trade under the new symbol SESN, effective on May 17. More news on: Eleven Biotherapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more …

 

Eleven Biotherapeutics Announces Corporate Name Change to Sesen Bio (2018-05-16 06:30 Business Wire)

Name Change Reflects Companys Focus on Late-Stage Oncology Drug Development Appointments of Senior Medical Advisor and Vice President of Regulatory Affairs Strengthen Leadership Team as Company Prepares for Phase 3 Three-month NMIBC Data Eleven Biotherapeutics, Inc. (Nasd…

 

After Hours Gainers / Losers (05/15/2018) (2018-05-15 17:35 SeekingAlpha)

Top gainers: BOOT +8.4% . ACRX +3.6% . EBIO +3.4% . PETQ +3.1% . SUPV +2.8% . More news on: Boot Barn Holdings, AcelRx Pharmaceuticals, Inc., Eleven Biotherapeutics, Inc., Stocks on the move, , News on ETFs, Read more …

 

Eleven Biotherapeutics beats by $0.02 (2018-05-15 16:46 SeekingAlpha)

Eleven Biotherapeutics (NASDAQ: EBIO ): Q1 EPS of -$0.11 beats by $0.02 . Cash and equivalents of $19.7M Shares +3.4% . Press Release More news on: Eleven Biotherapeutics, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, ,

 


Statistics

Shares Outstanding: 47.79M

Top 15 Institution Percent: 14.20

Price To Sales: N/A

Price To Book: 7.02

Revenue: N/A

Gross Profit: N/A

Cash: 27.09M

Debt: N/A

Return On Assets: -32.40

Return On Equity: -102.38

Profit Margin: N/A

Price History

Beta: 2.85

50-day Moving Avg: 1.80

200-day Moving Avg: 1.23

YTD Change: N/A

5-day Change: 25.57

1-month Change: 108.23

3-month Change: N/A

6-month Change: N/A

1-year Change: 100.61

Revenue Per Share: 0.00

Revenue Per Employee: 0.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Eleven Biotherapeutics Inc.

Exchange: NASDAQ Global Market

Industry: Biotechnology

Sector: Healthcare

Website: http://www.elevenbio.com

Eleven Biotherapeutics Inc is a biotechnology-based firm in the United States. It is engaged in the development of therapeutics to cure diseases related to the eye.